Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponezumab in Cerebral Amyloid Angiopathy
NCT01821118Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2013
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of ponezumab in cerebral amyloid angiopathy (CAA), sponsored by Pfizer. Started Jun 2013; status: completed.
02
Drugs
ponezumab
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NCT01821118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01821118.